Pharmaceutical Company CEO Developing $100 Alternative To EpiPen After 'Shameful' Price Hike
September 4, 2016
Mark Baum, CEO of Imprimis Pharmaceuticals who previously came out with a $1 alternative to Martin Shkreli's AIDS drug after 5000% price hike, is now going to take on Mylan and is plotting to offer a $100 EpiPen alternative.

Mark Baum / Imprimis Pharmceuticals
Baum believes the relentless EpiPen price hikes are "shameful" and plans to have a compounded version of the allergy treatment by the end of the year.
"I don't need to make $19 million a year," Baum said, referring to the big pay package Mylan's CEO Heather Bresch took home last year.
"Tonight when I go home I'm going to eat a nice piece of fish and the fish I eat isn't any better or worse than what she is going to eat."
Dogs Are Forced To Wear The Things They Steal — And It’s Hilarious
Meet Chonkers - The 2,000-Pound Sea Lion Taking Over San Francisco’s Pier 39
Mom Left Speechless After Reading Son’s Mother’s Day School Assignment
This Groundhog’s Dig Revealed a 19,000-Year-Old Secret
Meet Casper, the Single Owl Mom Who Has Raised More Than 500 Orphaned Babies
They Put a German Shepherd in Charge of Babysitting a Group of Doberman Puppies
Dog Watches Man Throw Football on TV and Has the Most Hilarious Reaction
UPS Driver Hailed a Hero After Saving Little Calf
Retired Dad Finds His True Calling Cuddling Babies in the NICU
Student Gets Teacher’s Handwritten Words Tattooed on Her and His Reaction Says Everything
